| Recruiting | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults Chronic Idiopathic Constipation (CIC) | Phase 3 | 2026-01-13 |
| Recruiting | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 2 | 2024-07-24 |
| Completed | An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females Lactation | Phase 1 | 2023-11-27 |
| Enrolling By Invitation | Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | 2023-02-17 |
| Recruiting | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | 2022-11-15 |
| Completed | A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia Hyperkalemia | Phase 2 | 2021-01-11 |
| Completed | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 4 | 2020-11-20 |
| Completed | A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Hyperphosphatemia, End Stage Renal Disease | Phase 4 | 2019-06-15 |
| Completed | Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Hyperphosphatemia | Phase 2 / Phase 3 | 2019-02-28 |
| Completed | A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Hyperphosphatemia | Phase 3 | 2018-01-08 |
| Terminated | A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia Hyperkalemia | Phase 2 | 2017-01-01 |
| Completed | A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C Constipation Predominant Irritable Bowel Syndrome | Phase 3 | 2016-03-01 |
| Completed | An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patient Hyperphosphatemia | Phase 3 | 2016-01-01 |
| Completed | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C Constipation Predominant Irritable Bowel Syndrome | Phase 3 | 2015-12-01 |
| Completed | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor fo Constipation Predominant Irritable Bowel Syndrome | Phase 3 | 2015-10-01 |
| Completed | To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers Healthy Volunteers | Phase 1 | 2014-05-01 |
| Completed | To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers Healthy Volunteers | Phase 1 | 2014-05-01 |
| Completed | AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study Healthy Volunteers | Phase 1 | 2014-04-01 |
| Completed | Dose Finding Study to Treat High Phosphate Levels in the Blood. Hyperphosphatemia | Phase 2 | 2014-03-01 |
| Completed | The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) Constipation Predominant Irritable Bowel Syndrome | Phase 2 / Phase 3 | 2013-08-01 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subj Healthy Volunteer | Phase 1 | 2013-07-01 |
| Completed | A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Chronic Kidney Disease, Type 2 Diabetes Mellitus | Phase 2 | 2013-05-01 |
| Completed | A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 Healthy | Phase 1 | 2013-04-01 |
| Completed | D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects Healthy Volunteers Food Interaction Study | Phase 1 | 2013-03-01 |
| Completed | A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations Healthy | Phase 1 | 2013-02-01 |
| Completed | Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD | Phase 2 | 2013-01-01 |
| Completed | Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers Healthy | Phase 1 | 2011-07-01 |
| Completed | A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Constipation Predominant Irritable Bowel Syndrome | Phase 2 | 2011-05-01 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers Healthy | Phase 1 | 2010-11-01 |